Episode Player

Join A pinch of salt, as we sit down with David Jayne to trace the rapid transformation of ANCA-associated vasculitis care. From the historic cyclophosphamide–glucocorticoid backbone to biologics like rituximab and newer targeted strategies such as complement inhibition (including avacopan), this episode unpacks how clinicians can balance efficacy, safety, and quality of life—while looking ahead to what may define the next decade of treatment.